|
1
|
Yamagami W, Nagase S, Takahashi F, Ino K,
Hachisuga T, Aoki D and Katabuchi H: Clinical statistics of
gynecologic cancers in Japan. J Gynecol Oncol. 28:e322017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tran AQ and Gehrig P: Recent advances in
endometrial cancer. F1000Res. 6:812017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Żyła MM, Wilczyński JR, Kostrzewa M,
Księżakowska-Łakoma K, Nowak M, Stachowiak G, Szyłło K and
Stetkiewicz T: The significance of markers in the diagnosis of
endometrial cancer. Prz Menopauzalny. 15:176–185. 2016.PubMed/NCBI
|
|
4
|
Salvesen HB, Iversen OE and Akslen LA:
Prognostic significance of angiogenesis and Ki-67, p53, and p21
expression: A population-based endometrial carcinoma study. J Clin
Oncol. 17:1382–1390. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715.
1984.PubMed/NCBI
|
|
6
|
Schwarting R, Gerdes J, Niehus J, Jaeschke
L and Stein H: Determination of the growth fraction in cell
suspensions by flow cytometry using the monoclonal antibody Ki-67.
J Immunol Methods. 90:65–70. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kosmas K, Stamoulas M, Marouga A,
Kavantzas N, Patsouris E and Athanassiadou P: Expression of Ki-67
as proliferation biomarker in imprint smears of endometrial
carcinoma. Diagn Cytopathol. 41:212–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masjeed NMA, Khandeparkar SGS, Joshi AR,
Kulkarni MM and Pandya N: Immunohistochemical study of ER, PR, Ki67
and p53 in endometrial hyperplasias and endometrial carcinomas. J
Clin Diagn Res. 11:EC31–EC34. 2017.PubMed/NCBI
|
|
10
|
Yang B, Shan B, Xue X, Wang H, Shan W,
Ning C, Zhou Q, Chen X and Luo X: Predicting lymph node metastasis
in endometrial cancer using serum CA125 combined with
immunohistochemical markers PR and Ki67, and a comparison with
other prediction models. PLoS One. 11:e01551452016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitson S, Sivalingam VN, Bolton J, McVey
R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse
T, et al: Ki-67 in endometrial cancer: Scoring optimization and
prognostic relevance for window studies. Mod Pathol. 30:459–468.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watanabe J, Kamata Y, Seo N, Okayasu I and
Kuramoto H: Stimulatory effect of estrogen on the growth of
endometrial cancer cells is regulated by cell-cycle regulators. J
Steroid Biochem Mol Biol. 107:163–171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kyushima N, Watanabe J, Hata H, Jobo T,
Kameya T and Kuramoto H: Expression of cyclin A in endometrial
adenocarcinoma and its correlation with proliferative activity and
clinicopathological variables. J Cancer Res Clin Oncol.
128:307–312. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Watanabe J, Nishimura Y, Tsunoda S,
Kawaguchi M, Okayasu I and Kuramoto H: Liquid-based preparation for
endometrial cytology-usefulness for predicting the prognosis of
endometrial carcinoma preoperatively. Cancer. 117:254–263.
2009.PubMed/NCBI
|
|
15
|
Kato N, Watanabe J, Jobo T, Nishimura Y,
Fujisawa T, Kamata Y and Kuramoto H: Immunohistochemical expression
of cyclin E in endometrial adenocarcinoma (endometrioid type) and
its clinicopathological significance. J Cancer Res Clin Oncol.
129:222–226. 2003.PubMed/NCBI
|
|
16
|
Nishimura Y, Watanabe J, Jobo T, Kato N,
Fujisawa T, Kamata Y and Kuramoto H: Cyclin D1 expression in
endometrioid-type endometrial adenocarcinoma is correlated with
histological grade and proliferative activity, but not with
prognosis. Anticancer Res. 24:2185–2191. 2004.PubMed/NCBI
|
|
17
|
Sobczak-Thepot J, Harper F, Florentin Y,
Zindy F, Brechot C and Puvion E: Localization of cyclin A at the
sites of cellular DNA replication. Exp Cell Res. 206:43–48. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Desdouets C, Sobczak-Thépot J, Murphy M
and Bréchot C: Cyclin A: Function and expression during cell
proliferation. Prog Cell Cycle Res. 1:115–123. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Santala S, Talvensaari-Mattila A, Soini Y,
Honkavuori-Toivola M and Santala M: High expression of cyclin A is
associated with poor prognosis in endometrial endometrioid
adenocarcinoma. Tumour Biol. 35:5395–5399. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shih HC, Shiozawa T, Kato K, Imai T,
Miyamoto T, Uchikawa J, Nikaido T and Konishi I:
Immunohistochemical expression of cyclins, cyclin-dependent
kinases, tumor-suppressor gene products, Ki-67, and sex steroid
receptors in endometrial carcinoma: Positive staining for cyclin A
as a poor prognostic indicator. Hum Pathol. 34:471–478. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yam CH, Fung TK and Poon RY: Cyclin A in
cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Husdal A, Bukholm G and Bukholm IR: The
prognostic value and overexpression of cyclin A is correlated with
gene amplification of both cyclin A and cyclin E in breast cancer
patient. Cell Oncol. 28:107–116. 2006.PubMed/NCBI
|
|
24
|
Mrena J, Wiksten JP, Kokkola A, Nordling
S, Haglund C and Ristimäki A: Prognostic significance of cyclin A
in gastric cancer. Int J Cancer. 119:1897–1901. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paterlini P, Suberville AM, Zindy F, Melle
J, Sonnier M, Marie JP, Dreyfus F and Bréchot C: Cyclin A
expression in human hematological malignancies: A new marker of
cell proliferation. Cancer Res. 53:235–238. 1993.PubMed/NCBI
|
|
26
|
Nishida M, Kasahara K, Kaneko M, Iwasaki H
and Hayashi K: Establishment of a new human endometrial
adenocarcinoma cell line, Ishikawa cells, containing estrogen and
progesterone receptors. Nihon Sanka Fujinka Gakkai Zasshi.
37:1103–1111. 1985.(In Japanese). PubMed/NCBI
|
|
27
|
Nishida M, Kasahara K, Oki A, Satoh T,
Arai Y and Kubo T: Establishment of eighteen clones of Ishikawa
cells. Hum Cell. 9:109–116. 1996.PubMed/NCBI
|
|
28
|
Kuramoto H, Hamamo M, Nishida M, Toguchi
A, Jobo T, Suzuki M and Osanai K: Establishment of a cell line of
human endometrial carcinoma originated from ascitic fluid. Acta
Obstet Gynaecol Jpn. 28:1405–1406. 1976.
|
|
29
|
Nordström B, Strang P, Bergström R,
Nilsson S and Tribukait B: A comparison of proliferation markers
and their prognostic value for women with endometrial carcinoma.
Ki-67, proliferating cell nuclear antigen, and flow cytometric
S-phase fraction. Cancer. 78:1942–1951. 1996. View Article : Google Scholar : PubMed/NCBI
|
